Amgen's Phase 3 Sjögren's Drug Succeeds, Boosting Horizon Deal
A phase 3 trial shows Amgen's fusion protein significantly reduces Sjögren's disease severity, offering a rare win for its Horizon Therapeutics acquisition.
Amgen announced that its investigational fusion protein, acquired through the Horizon Therapeutics deal, significantly eased the severity of Sjögren's disease in a phase 3 trial. The result is a bright spot for the company's pipeline, which has faced challenges in delivering wins since the acquisition.
The trial's success suggests the drug could become a new treatment option for Sjögren's, an autoimmune condition with limited therapies. However, the source does not provide specific efficacy data or safety details, so the magnitude of the benefit and potential risks remain unclear.
This is the only source available, so there are no conflicting reports. The outcome may help validate Amgen's $27.8 billion bet on Horizon, though broader commercial potential and regulatory hurdles are yet to be assessed.
Sources · 3
More in Medicine & Biotech
Rare Pregnancy Infections Linked to Autism and Intellectual Disability
A Karolinska Institutet study in JAMA Pediatrics finds that rare fetal infections are associated with higher risks of autism and intellectual disability.
Brain may be two fused organs, Stanford study suggests
New research indicates the human brain develops from two distinct cellular systems, hinting that evolution fused two ancient nervous systems.
Hidden Gut Defect in Remission May Explain IBD Relapses
A lingering molecular warning sign in gut tissue may explain why inflammatory bowel disease keeps returning.
AI turns unstructured clinical data into research-ready variables
A new analysis highlights how AI can help healthcare organizations convert fragmented, unstructured data into structured variables, addressing a major bottleneck in clinical research.